PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia

PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia

Immune therapies such as blinatumomab, CD19-directed bispecific CD3 T-cell Engager (BiTE), have resulted in significant improvements in outcomes for relapsed B-cell acute lymphoblastic leukemia (B-ALL). However, up to half of blinatumomab treated patients do not respond completely or relapse after t...

Full description

Bibliographic Details
Main Authors: Mark Wunderlich, Nicole Manning, Christina Sexton, Eric O’Brien, Luke Byerly, Cody Stillwell, John P. Perentesis, James C. Mulloy, Benjamin Mizukawa
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
patient derived xenograft
blinatumomab
pembrolizumab
B-ALL
humanized mice
immune checkpoint inhibition
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.642466/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.642466/full

Similar Items